Log in to search using one of your social media accounts:

 

Mylan rolls out HIV treatment medicine in Canada
Mylan launched three generic medications to treat HIV in Canada. The pharmaceutical company, which is based in the Netherlands but run out of its corporate offices in Canonsburg, said it had received Health Canada approval for these generic drugs: emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg, a generic alternative to Truvada efavirenz/emtricitabin e/tenofovir disoproxil fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla tenofovir disoproxil 300 mg, a generic alternative… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 10, 2017 Category: American Health Authors: Paul J. Gough Source Type: news

Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan now offers generic alternatives to Truvada®, Atripla® and Viread® to patients in Canada1 HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan Pharmaceuticals ULC, a subsid... Biopharmaceuticals, Generics, Product Launch Mylan, Truvada, Atripla, Viread (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 10, 2017 Category: Pharmaceuticals Source Type: news

Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz
Exposure of infants, from conception, to the antiretroviral combination of tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TFC-FTC-EFV) is associated with a lower risk of adverse birth outcomes, compared with exposure to other antiretroviral regimens, according to data from Botswana.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Atripla (Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 24, 2017 Category: Drugs & Pharmacology Source Type: news

HIV: Complera Non-Inferior to Atripla (CME/CE)
(MedPage Today) -- Single-tablet fixed-dose combinations successfully suppress HIV (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - July 21, 2016 Category: Infectious Diseases Source Type: news

Will German Regulators Dampen Gilead Hopes For Its Stribild AIDS Drug?
German regulators have issued a preliminary decision that the Gilead Sciences once-daily, combination Stribild HIV treatment does not offer a benefit over the older Atripla medication. Gilead is appealing, but if regulators remain firm, the drugmaker may face 'referenced' pricing - Stribild would be lowered to the Atripla price and if other European Union countries adopt the same, the value if fixed-dose regimen products could be diminished. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 18, 2013 Category: Pharmaceuticals Authors: Ed Silverman Source Type: news

FDA Approves Dolutegravir, a New Drug to Treat HIV-1 Infection
“The U.S. Food and Drug Administration today [August 12, 2013] approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection.   “Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. It is a pill taken daily in combination with other antiretroviral drugs.   “Tivicay is approved for use in a broad population of HIV-infected patients. It can be used to treat HIV-infected adults who have never taken HIV therapy (treatment-naïve) and HIV-infected adults who have previously taken HIV therapy (treatment-experienced), includ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 16, 2013 Category: Infectious Diseases Source Type: news

One Pill or Three? Conflicting Research Puts HIV Generics in the Spotlight
On the face of things, the strategy makes perfect sense. With the patent expiring on one of the three drugs in Atripla (the once-daily, single-pill antiretroviral used in first-line therapy in the U.S.), why not save money by using a cheap generic version of first drug (Sustiva), replacing the second (Emtriva) with a suitable generic (Epivir), and offering the branded drug component (Viread) on its own? Drug coverage providers in the U.S. could potentially save up to $1 billion per year, said an investigative team from Harvard Medical School this past July....Read Full Post (Source: About AIDS / HIV)
Source: About AIDS / HIV - May 15, 2013 Category: Consumer Health News Source Type: news

FDA Updates Atripla Labeling
“FDA recently approved updates to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes: Lists Stribild as one of the drugs that should not be coadministered with Atripla Adds drug interaction information for raltegravir, boceprevir and telaprevir Strengthens Warnings and Precautions: Rash section Updates the Use in Specific Populations: Nursing Mothers section Updates Tables 7 and 8 with didanosine drug interaction data based upon recent changes to the prescribing information for Sustiva, Truvada and Viread.” The updated labeling will be a...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 19, 2013 Category: Infectious Diseases Source Type: news

Co-formulated elvitegravir / cobicistat / emtricitabine / tenofovir (QUAD)
Source: London New Drugs Group Area: Evidence> Drug Specific Reviews The new QUAD tablet consists of three antiretrovirals, elvitegravir, emtricitabine and tenofovir, and a booster, cobicistat. UK launch is anticipated in Q2 2013, subject to EU approval. It is the first single-tablet regimen to combine a once-daily integrase inhibitor (elvitegravir) which is boosted by a first-in-class pharmacoenhancer (cobicistat), plus a preferred backbone of emtricitabine and tenofovir. Two phase III studies have been carried out:  Study 102 and 103, comparing QUAD to Atripla (Study 102) and to atazanavir/ritonavir plus...
Source: NeLM - Drug Specific Reviews - January 22, 2013 Category: Drugs & Pharmacology Source Type: news